Get the Stockscreener App
20.67
0.53%
-0.11
After Hours:
20.66
-0.01
-0.05%
Summit Therapeutics Inc Stock (SMMT) Latest News
Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 5.4%Here's Why - MarketBeat
Calamos Advisors LLC Cuts Stock Holdings in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Summit Therapeutics Inc. (NASDAQ:SMMT) Receives $33.57 Average Price Target from Brokerages - MarketBeat
China Universal Asset Management Co. Ltd. Buys 17,014 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Five Pine Wealth Management Makes New Investment in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Summit Therapeutics (SMMT): Jim Cramer Calls It a ‘Very Big Spec’ - Insider Monkey
Jim Cramer Says AppFolio Is A 'Good One,' But Summit Therapeutics? 'Can't Go There' - Benzinga
Summit Therapeutics Inc. (NASDAQ:SMMT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Up More Than 500% in 12 Months, Is It Too Late to Buy Summit Therapeutics Stock? - MSN
Griffin Asset Management Inc. Purchases 42,900 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Lightning Round: I don't want to sell Adobe down here, says Jim Cramer - MSN
(SMMT) Investment Report - Stock Traders Daily
Is Summit Therapeutics Inc. (SMMT) the Unstoppable Stock to Buy in 2025? - Yahoo Finance
Why This Beaten-Down Stock Is a Buy in 2025 and Beyond - The Motley Fool
Netflix, Palantir And Moderna Are Among Top 12 Large Cap Gainers Last Week (Jan 20-Jan 24): Are The Others In Your Portfolio? - Benzinga
Assenagon Asset Management S.A. Makes New $229,000 Investment in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Assenagon Asset Management S.A. Buys New Stake in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Why Summit Therapeutics (SMMT) Is Skyrocketing Now - Yahoo Finance
Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 4.7%Time to Sell? - MarketBeat
Summit Therapeutics announces executive compensation changes - MSN
Summit Therapeutics retains Buy stock rating on clinical trial - MSN
Summit Therapeutics announces executive compensation changes By Investing.com - Investing.com Canada
Summit Therapeutics Grants Bonuses and Reports Strong Finances - TipRanks
Why Summit Therapeutics Stock Is Jumping Today - MSN
Cancer therapy’s new ‘gold rush’: bispecific antibodies that hit key combination of targets - STAT
HC Wainwright Reaffirms Buy Rating for Summit Therapeutics (NASDAQ:SMMT) - MarketBeat
Summit Therapeutics’ (SMMT) Buy Rating Reaffirmed at HC Wainwright - Defense World
Summit Therapeutics' (SMMT) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Summit Therapeutics retains Buy stock rating on clinical trial By Investing.com - Investing.com Canada
12 Hot Stocks to Buy According to Analysts - Insider Monkey
Here’s Why Analysts Are Bullish on Summit Therapeutics Inc. (SMMT) - Yahoo Finance
Long Term Trading Analysis for (SMMT) - Stock Traders Daily
JPMorgan Chase & Co. Sells 1,101 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Is Summit Therapeutics (SMMT) the Best Russell 2000 Stock to Invest in According to Analysts? - MSN
Summit Therapeutics (SMMT) Stock Price, News & Analysis - MarketBeat
Summit Therapeutics (NASDAQ:SMMT) Trading 6.5% HigherWhat's Next? - MarketBeat
Summit Therapeutics: Data Signals A Potential Paradigm Shift In NSCLC (Rating Upgrade) - Seeking Alpha
Summit Therapeutics (NASDAQ:SMMT) Trading Down 6.3%Here's What Happened - MarketBeat
Looking At Summit Therapeutics's Recent Unusual Options Activity - Benzinga
0.12%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):